| 2020 | Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer | BREAST CANCER RESEARCH AND TREATMENT |
| 2020 | Local Treatment in Addition to Endocrine Therapy in Hormone Receptor-Positive and HER2-Negative Oligometastatic Breast Cancer Patients: A Retrospective Multicenter Analysis | BREAST CARE |
| 2020 | Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study | ANNALS OF ONCOLOGY |
| 2020 | Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer
| EXPERIMENTAL AND MOLECULAR MEDICINE |
| 2020 | Intermediate HER2 Expression Is Associated With Poor Prognosis in Estrogen Receptor-Positive Breast Cancer Patients Aged 55 Years and Older | BREAST CANCER RESEARCH AND TREATMENT |
| 2019 | Establishment of Chemosensitivity Tests in Triple-Negative and BRCA-mutated Breast Cancer Patient-Derived Xenograft Models
| PLOS ONE |
| 2019 | Risk of Lymphedema Following Contemporary Treatment for Breast Cancer: An Analysis of 7617 Consecutive Patients From a Multidisciplinary Perspective | EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION |
| 2019 | 차세대 염기서열 분석법과 항암요법
| JOURNAL OF THE KOREAN MEDICAL ASSOCIATION |
| 2019 | Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)
| CANCER RESEARCH AND TREATMENT |
| 2019 | Effect of primary tumor resection on overall survival in patients with stage IV breast cancer | BREAST JOURNAL |
| 2019 | A Phase II Study to Evaluate the Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients Receiving Dose-Dense Doxorubicin/Cyclophosphamide
| CANCER RESEARCH AND TREATMENT |
| 2018 | Differential Prognostic Impact of Strong PD-L1 Expression and 18F-FDG Uptake in Triple-negative Breast Cancer | AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS |
| 2018 | External validation of IBTR! 2.0 nomogram for prediction of ipsilateral breast tumor recurrence
| Radiation Oncology Journal |
| 2018 | Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials. | JOURNAL OF GLOBAL ONCOLOGY |
| 2018 | Feasibility of Charcoal Tattooing of Cytology-Proven Metastatic Axillary Lymph Node at Diagnosis and Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients
| CANCER RESEARCH AND TREATMENT |
| 2018 | Locoregional Treatment of the Primary Tumor in Patients With De Novo Stage IV Breast Cancer: A Radiation Oncologist's Perspective | CLINICAL BREAST CANCER |
| 2018 | The Benefit of Pro Re Nata Antiemetics Provided With Guideline-Consistent Antiemetics in Delayed Nausea Control | CANCER NURSING |
| 2018 | CD44/CD24 and aldehyde dehydrogenase 1 in estrogen receptor-positive early breast cancer treated with tamoxifen: CD24 positivity is a poor prognosticator
| ONCOTARGET |
| 2017 | Next-generation sequencing of BRCA1/2 in breast cancer patients: potential effects on clinical decision-making using rapid, high-accuracy genetic results
| ANNALS OF SURGICAL TREATMENT AND RESEARCH |
| 2017 | An Open-Label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer | CANCER RESEARCH AND TREATMENT |
| 2017 | Meeting Highlights: The Second Consensus Conference for Breast Cancer Treatment in Korea
| JOURNAL OF BREAST CANCER |
| 2017 | Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer | BREAST CANCER RESEARCH AND TREATMENT |
| 2017 | Chemotherapy-induced irreversible alopecia in early breast cancer patients | BREAST CANCER RESEARCH AND TREATMENT |
| 2017 | Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study | EUROPEAN JOURNAL OF CANCER |
| 2017 | Detection of Circulating Tumor Cells in Breast Cancer Patients Using Cytokeratin-19 Real-Time RT-PCR
| YONSEI MEDICAL JOURNAL |
| 2017 | Comparison of standardized uptake value of 18F-FDG-PET-CT with 21-gene recurrence score in estrogen receptor-positive, HER2-negative breast cancer
| PLOS ONE |
| 2016 | Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study
| CANCER RESEARCH AND TREATMENT |
| 2016 | Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy
| JOURNAL OF BREAST CANCER |
| 2016 | The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast Cancer.
| PLOS ONE |
| 2016 | Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer
| ONCOTARGET |
| 2016 | Magnetic Resonance Imaging after Completion of Neoadjuvant Chemotherapy Can Accurately Discriminate between No Residual Carcinoma and Residual Ductal Carcinoma In Situ in Patients with Triple-Negative Breast Cancer
| PLOS ONE |
| 2015 | Detection of circulating tumor cell-specific markers in breast cancer patients using the quantitative RT-PCR assay | INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY |
| 2015 | Prediction of short- and long-term survival for advanced cancer patients after ICU admission | SUPPORTIVE CARE IN CANCER |
| 2015 | Do Recent Advances in Diagnostic and Therapeutic Procedures Negate the Benefit of Postmastectomy Radiotherapy in N1 Patients With a Low Risk of Locoregional Recurrence?
| MEDICINE |
| 2015 | 성장인자수용체-2 양성 유방암 조직에서 표적치료 전후의 성장인자수용체군 발현양상
| Korean Journal of Clinical Oncology (대한임상종양학회지) |
| 2015 | Anaplastic lymphoma kinase gene copy number gain in inflammatory breast cancer (IBC): prevalence, clinicopathologic features and prognostic implication
| PLOS ONE |
| 2014 | cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer
| JOURNAL OF CANCER |
| 2014 | Patient-Reported Outcomes From EMILIA, a Randomized Phase 3 Study of Trastuzumab Emtansine (T-DM1) Versus Capecitabine and Lapatinib in Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Breast Cancer | CANCER |
| 2013 | A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer | INVESTIGATIONAL NEW DRUGS |
| 2013 | Prolonged clinical benefit from the maintenance hormone therapy in patients with metastatic breast cancer | BREAST |
| 2013 | S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial
| BMC CANCER |
| 2013 | Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapy
| ANNALS OF ONCOLOGY |
| 2013 | Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors
| SUPPORTIVE CARE IN CANCER |
| 2013 | Multicentre phase II trial of bevacizumab combined with docetaxel–carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905)
| ANNALS OF ONCOLOGY |
| 2012 | Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy
| PLOS ONE |
| 2012 | Prediction of outcomes for patients with brain parenchymal metastases from breast cancer (BC): a new BC-specific prognostic model and a nomogram
| NEURO-ONCOLOGY |
| 2012 | Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. | LANCET |
| 2012 | Metaplastic breast cancer: clinicopathological features and its prognosis | JOURNAL OF CLINICAL PATHOLOGY |
| 2011 | Active targeting and safety profile of PEG-modified adenovirus conjugated with herceptin | BIOMATERIALS |
| 2011 | Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen. | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY |
http://orcid.org/0000-0002-2303-2764
(15045889800)
